端粒与端粒酶研究进展

细胞分裂中染色体因其末端（端粒）的DNA不能完全复制而短缩,使细胞逐渐失去增殖能力而衰老．端粒酶可延长染色体末端DNA,端粒酶的活化使细胞无限增殖．85％左右的恶性肿瘤端粒酶表达阳性,生殖细胞和无限繁殖的细胞系中端粒酶表达也呈阳性．文章综述了端粒的构成和功能、端粒酶在端粒合成中的作用,介绍了端粒酶活性的测定方法、细胞恶变与端粒酶激活的关系,并论及通过抑制端粒酶活性来治疗癌症的可能性．     

依赖端粒酶的端粒维持机制

端粒是真核生物染色体的末端重要结构复合物,对维持染色体稳定性起着重要作用。端粒酶的主要功能是复制端粒末端DNA,维持端粒长度。端粒酶活性调节与肿瘤发生和细胞衰老有着密切关系。本简要综述近年来依赖端粒酶的端粒维持机理的研究进展。     

端粒及端粒酶研究的最新进展

端粒是位于真核细胞染色体末端由重复DNA序列和蛋白组成的复合物,它具有保护染色体、介导染色体复制、引导减数分裂时的同源染爸体配对和调节细胞衰老等方面的作用。正常体细胞每分裂一代,端粒就会缩短一段,而端粒酶的作用是将一段端粒序列加到端粒末端,从而维持端粒长度。正常体细胞中是没有端粒酶活性的,而在大多数肿瘤细胞中都发现了端粒酶的表达,提示端粒和端粒酶在癌症发生和肿瘤细胞行为中具有重要作用。     

端粒及端粒酶的研究进展

端粒是染色体末端独特的蛋白质-DNA结构,在保护染色体的完整性和维持细胞的复制能力方面起着重要的作用.端粒酶则是由RNA和蛋白质亚基组成的、能够延长端粒的一种特殊反转录酶.端粒长度和端粒酶活性的变化与细胞衰老和癌变密切相关.端粒结合蛋白可能通过调节端粒酶的活性来调节端粒长度,进而控制细胞的衰老、永生化和癌变.研制端粒酶的专一性抑制剂在肿瘤治疗方面有着广阔的前景.     

HeLa细胞端粒酶最适反应条件及活性重建

端粒是真核细胞染色体末端的重复ＤＮＡ序列 ,其生物学功能是防止染色体ＤＮＡ降解、末端融合、非正常重组和染色体的缺失[1] .由于存在“末端复制问题” ,随着老化人体细胞端粒重复序列长度不断缩短 ,但在生殖细胞中由于端粒酶的存在 ,端粒序列并不缩短 .端粒酶是由蛋白质和ＲＮＡ构成的核蛋白 ,是依赖ＲＮＡ的ＤＮＡ聚合酶 ,在ＤＮＡ3’端合成端粒重复序列[2 ] .研究表明 ,在 85 %～ 95 %的人肿瘤细胞中可以检测到端粒酶的活性[3 ,4 ] ,而在正常体细胞中除生殖细胞和造血干细胞等极少数细胞中存在端粒酶活性外 ,均检测不到端粒酶活性 ,这…     

端粒、端粒酶与肿瘤

端粒是真核细胞染色体末端含有 TTAGGG简单重复结构的复合体 ,它能防止染色体降解 ,端端融合 ,重组降解 ,因而有稳定染色体的作用。正常情况下 ,由于染色体复制的自身缺陷 ,细胞每分裂一次端粒要丢失 2 0～ 50 %碱基对 ,随着细胞分裂的增加 ,最终使细胞进入危机期 ,导致细胞死亡。端粒酶是一种 RNA、蛋白质的复合体 ,以 RNA为模板逆转录合成染色体末端的端粒 ,以维持染色体的稳定性。目前研究肿瘤组织细胞端粒酶活性高达 85～ 90 % ,而在正常组织细胞端粒酶活性较低。因此 ,端粒酶与肿瘤关系密切 ,端粒酶的研究成为国内外肿瘤的热点之…     

哺乳动物早期胚胎端粒和端粒酶重编程

端粒位于真核染色体末端,是稳定染色体末端的重要元件。端粒酶(TER)是一种特殊的细胞核糖核蛋白(RNP)反转录酶(RT),其核心酶包括蛋白亚基和RNA元件。在DNA复制过程中的端粒丢失可以被有活性的端粒酶修复回来。哺乳动物端粒酶在发育中受调控,端粒的重编程可能是由于早期胚胎不同时期的端粒酶活性而造成的。因此,研究端粒和端粒酶重编程在早期胚胎发育中是非常重要的。该文综述了端粒和端粒酶的结构和功能,及其与哺乳动物早期胚胎发育的关系,并在此基础上展望了端粒和端粒酶在克隆动物胚胎发育的基础研究。     

端粒酶及其抑制剂的研究进展

细胞分裂中染色体因其末端的DNA不能完全复制而短缩,使细胞逐渐失去增殖能力,导致细胞衰老、死亡。端粒酶的活化可延长染色体的末端DNA,维护基因组的稳定。端粒酶活性的异常表达,又会使细胞永生化或转化成癌细胞。因此,端粒酶在控制细胞寿命方面有重要作用,端粒酶活性抑制剂有望成为治疗肿瘤的新药物。     

端粒酶抑制剂在肿瘤治疗中的进展

端粒是真核细胞染色体末端含有ＴＴＡＧＧＧ重复结构的复合体 ,有防止染色体降解丢失 ,端端融合和重组建作用 ,端粒酶是一种逆转录酶 ,以自身ＲＮＡ为模板 ,逆转录维持染色体的稳定。目前肿瘤组织端粒酶检出率约 85 - 90 %,而正常组织或良性肿瘤端粒酶检出率〈5 %,说明端粒酶与恶性肿瘤密切相关。端粒酶抑制剂作为新的抗肿瘤策略正成为肿瘤研究的热点 ,现就端粒酶抑制剂在肿瘤治疗中的研究状况做一简单概述。1、阻断端粒酶ＲＮＡ的模板作用对端粒酶活性的抑制1. 1反义核苷酸、反义肽苷及硫代反义核苷酸对端粒酶活性的抑制端粒酶ＲＮＡ序列中…     

端粒酶研究的若干进展

端粒酶是一种ＲＮＡ依赖的ＤＮＡ聚合酶。它的生物学功能在于以自身的ＲＮＡ为模板,合成端粒序列,解决了线性染色体的末端复制问题,维持了染色体的稳定性。本文介绍一些新进展：如端粒酶蛋白的ｃＤＮＡ已被克隆;端粒酶活性检测中出现误差的可能原因;端粒酶活性的调控因子ＴＲＦ１及新发现的ＴＲＦ２;端粒酶活性同肿瘤诊断及预后间的关系;端粒酶的激活同肿瘤发生间的关系;反义核酸抑制端粒酶活性的可能性及其可能发生的问题等。     

荧光定量PCR 法检测肿瘤细胞端粒酶活性的变化

目的：利用荧光定量PCR法检测端粒酶抑制剂作用于人肝癌细胞SMMC-7721后端粒酶活性的变化,探讨其抑制端粒酶活性的可能机制,为端粒酶抑制剂的临床应用提供理论依据。方法：利用荧光染料SYBR—Green I建立一种新的端粒酶活性检测方法：FQ—TRAP法。利用FQ—TRAP法检测端粒酶抑制剂作用后肿瘤细胞端粒酶活性变化。结果：端粒酶抑制剂作用后,肝癌细胞端粒酶活性都有变化,其中以ASODN,EGCG,AZT抑制效果较明显。结论：端粒酶FQ—TRAP法是一种特异性、灵敏度、重复性都较好,可快速、简便及定量检测人端粒酶活性的方法,端粒酶抑制剂作用后癌细胞端粒酶活性的变化,为端粒酶抑制剂的临床应用提供理论依据。     

Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells.

Solid tumor cells are often exposed to hypoxia in vivo, which has been suggested to promote genetic instability in those cells. Telomere elongation by telomerase is implicated in chromosome stabilization in immortal cells. Here we found that hypoxia enhanced telomerase activity in the solid tumor A2780 and HT-29 cells but not in the leukemia U937 cells. The telomerase activation correlated with activation of mitogen-activated protein kinase (MAPK) and c-fos expression. The MEK1 inhibitor PD98059 repressed telomerase activation in the hypoxic cells. Consistently, a dominant negative MEK1 inhibited telomerase activation by hypoxia. Finally, we found a good correlation between telomerase activation and resistance to apoptotic cell death under hypoxic conditions. These findings indicate that hypoxia up-regulates telomerase activity via MAPK cascade signaling especially in solid tumor cells and suggest that solid tumor cells might enhance the telomerase activity as a stress response against genotoxicity induced by hypoxia.     

Telomerase activity coevolves with body mass not lifespan

In multicellular organisms, telomerase is required to maintain telomere length in the germline but is dispensable in the soma. Mice, for example, express telomerase in somatic and germline tissues, while humans express telomerase almost exclusively in the germline. As a result, when telomeres of human somatic cells reach a critical length the cells enter irreversible growth arrest called replicative senescence. Replicative senescence is believed to be an anticancer mechanism that limits cell proliferation. The difference between mice and humans led to the hypothesis that repression of telomerase in somatic cells has evolved as a tumor-suppressor adaptation in large, long-lived organisms. We tested whether regulation of telomerase activity coevolves with lifespan and body mass using comparative analysis of 15 rodent species with highly diverse lifespans and body masses. Here we show that telomerase activity does not coevolve with lifespan but instead coevolves with body mass: larger rodents repress telomerase activity in somatic cells. These results suggest that large body mass presents a greater risk of cancer than long lifespan, and large animals evolve repression of telomerase activity to mitigate that risk.     

Interactions between telomerase and primase physically link the telomere and chromosome replication machinery

In the ciliate Euplotes crassus, millions of new telomeres are synthesized by telomerase and polymerase alpha-primase during macronuclear development in mated cells. Concomitant with de novo telomere formation, telomerase assembles into higher-order complexes of 550 kDa, 1,600 kDa, and 5 MDa. We show here that telomerase is physically associated with the lagging-strand replication machinery in these complexes. Antibodies against DNA primase precipitated telomerase activity from all three complexes from mated cells but not the 280-kDa telomerase complex from vegetatively growing cells. Moreover, when telomerase was affinity purified, primase copurified with enzyme from mated cells but not with the 280-kDa vegetative complex. Thus, the association of telomerase and primase is developmentally regulated. Intriguingly, PCNA (proliferating cell nuclear antigen) was also found in the 5-MDa complex from mated cells. We therefore speculate that this complex is a complete telomere synthesis machine, while the smaller complexes are assembly intermediates. The physical association of telomerase and primase explains the coordinate regulation of telomeric G- and C-strand synthesis and the efficiency of telomere addition in E. crassus.     

New roles of Rb1 in expansion of MDSCs in cancer

Telomerase supports the proliferation of progenitor cells and tumor cells by adding telomere repeats to chromosome ends. The low abundance and restricted expression pattern of telomerase have limited our knowledge of this important enzyme. A new telomerase protein, TCAB1, sheds light on the pathway that governs telomerase holoenzyme assembly and function in vivo. TCAB1 is a component of active telomerase and is required for the telomerase holoenzyme to accumulate in Cajal bodies and to elongate telomeres. These findings provide important new insights into how telomerase functions in cancer and in stem cell biology.     

Clonal heterogeneity in telomerase activity and telomere length in tumor-derived cell lines

The ribonucleoprotein, telomerase, is responsible for the maintenance of telomere length in most immortal and cancer cells. Telomerase appears to be a marker of human malignancy with at least 85% of human cancers expressing its activity. In the present study, we examined a series of tumor-derived and in vitro immortalized cell lines for telomerase activity levels, telomere lengths, and expression levels of the RNA and catalytic components of telomerase. We found significant variability in both telomere lengths and telomerase activity in clones from tumor cells. In addition, the levels of telomerase components or telomerase activity were not predictive of telomere length. Data from clonally derived cells suggest that critically shortened telomeres in these tumor-derived cell lines may signal activation of telomerase activity through an increase in the expression of the catalytic subunit of telomerase. Although clones with low telomerase shorten their telomeres over time, their subclones all have high levels of telomerase activity with no telomere shortening. In addition, analysis of early clones for telomerase activity indicates substantial variability, which suggests that activity levels fluctuate in individual cells. Our data imply that cell populations exhibit a cyclic expression of telomerase activity, which may be partially regulated by telomere shortening.     

Studies of the molecular mechanisms in the regulation of telomerase activity.

Telomerase, a specialized RNA-directed DNA polymerase that extends telomeres of eukaryotic chromosomes, is repressed in normal human somatic cells but is activated during development and upon neoplasia. Whereas activation is involved in immortalization of neoplastic cells, repression of telomerase permits consecutive shortening of telomeres in a chromosome replication-dependent fashion. This cell cycle-dependent, unidirectional catabolism of telomeres constitutes a mechanism for cells to record the extent of DNA loss and cell division number; when telomeres become critically short, the cells terminate chromosome replication and enter cellular senescence. Although neither the telomere signaling mechanisms nor the mechanisms whereby telomerase is repressed in normal cells and activated in neoplastic cells have been established, inhibition of telomerase has been shown to compromise the growth of cancer cells in culture; conversely, forced expression of the enzyme in senescent human cells extends their life span to one typical of young cells. Thus, to switch telomerase on and off has potentially important implications in anti-aging and anti-cancer therapy. There is abundant evidence that the regulation of telomerase is multifactorial in mammalian cells, involving telomerase gene expression, post-translational protein-protein interactions, and protein phosphorylation. Several proto-oncogenes and tumor suppressor genes have been implicated in the regulation of telomerase activity, both directly and indirectly; these include c-Myc, Bcl-2, p21(WAF1), Rb, p53, PKC, Akt/PKB, and protein phosphatase 2A. These findings are evidence for the complexity of telomerase control mechanisms and constitute a point of departure for piecing together an integrated picture of telomerase structure, function, and regulation in aging and tumor development-Liu, J.-P. Studies of the molecular mechanisms in the regulation of telomerase activity.